InvestorsHub Logo
Followers 958
Posts 78620
Boards Moderated 6
Alias Born 02/01/2005

Re: FORDGT post# 387

Sunday, 02/26/2012 8:30:46 AM

Sunday, February 26, 2012 8:30:46 AM

Post# of 447
Watching this one since July of last year. Very interesting movement last few days, http://www.aidsmeds.com/articles/hiv_bevirimat_mpc4326_1667_18528.shtml

Though bevirimat had particular challenges, in that people who had resistance to protease inhibitors were less likely to benefit from the drug, the company said it had at least one backup compound if bevirimat proved ineffective.

It is unclear whether Myriad will sell these compounds to another company for further development.

Myriad had been developing a maturation inhibitor called bevirimat (MPC-4326, PA-457) since 2009, after purchasing the rights to the drug from Panacos Pharmaceuticals

New 52wkhi, something going on http://stockcharts.com/c-sc/sc?s=PANC&p=d&b=1&g=1&id=p17970548896


Looking further.....

sc